Okita Y, Takamoto S, Ando M, Morota T, Yamaki F, Kawashima Y
Department of Cardiovascular Surgery, National Cardiovascular Center, Osaka, Japan.
Circulation. 1996 Nov 1;94(9 Suppl):II177-81.
The perioperative blood coagulation and fibrinolysis system in patients who underwent aortic surgery under deep hypothermic circulatory arrest with or without aprotinin usage was investigated.
Of 112 patients who underwent aortic surgery between December 1993 and April 1995, 60 had repair under deep hypothermic circulatory arrest. Thirty-nine patients had 2 million U aprotinin in pump priming and had no additional aprotinin. There were 20 patients with aortic dissections and 17 with atherosclerotic aneurysms. Twenty-two patients had left thoracotomy, and 17 had midsternotomy. Surgery consisted of replacement of the ascending aorta in 9 patients, total arch replacement in 11, distal arch replacement in 11, replacement of the descending aorta in 3, and replacement of thoracoabdominal aorta in 5. The control group was 21 patients who underwent operation under deep hypothermic circulatory arrest and retrograde cerebral perfusion but without aprotinin. Blood coagulation and fibrinolysis tests, consisting of activated clotting time, prothrombin time, activated partial thromboplastin time, fibrinogen, antithrombin III, plasminogen, alpha 2-plasmin inhibitor, thrombin-antithrombin complex, plasmin inhibitor complex, fibrin degenerative products, and D-dimer complex, were performed at various stages of surgery, before heparin administration, after heparin, 60 minutes and 120 minutes after beginning of the extracorporeal circulation, 1 hour after protamine administration, and 6 hours after protamine. Statistical analysis was performed with Student's t test, chi 2 test, and ANOVA. The amount of bleeding after perfusion was less in the aprotinin group, and bleeding during first 24 hours in the intensive care unit was less. Blood examination revealed that prothrombin time was higher after cessation of cardiopulmonary bypass in the aprotinin group. Thrombin-antithrombin III complex and alpha 2-plasmin inhibitor were higher during and after bypass in the aprotinin group. There was no difference in activated clotting time, activated partial thromboplastin time, fibrinogen, antithrombin III, plasminogen, plasmin inhibitor complex, fibrin degenerative products, and D-dimer complex.
Clinical advantages of hemostatic effects of low-dose aprotinin and no apparent deleterious effects were demonstrated in patients who underwent aortic surgery under deep hypothermic circulatory arrest with retrograde cerebral perfusion. However, blood coagulation and fibrinolytic studies revealed subclinical hypercoagulation. Therefore, and adequate dose of heparin is required during deep hypothermic circulatory arrest.
对在深低温停循环下接受主动脉手术且使用或未使用抑肽酶的患者围手术期凝血和纤溶系统进行了研究。
在1993年12月至1995年4月期间接受主动脉手术的112例患者中,60例在深低温停循环下进行修复。39例患者在预充液中加入200万单位抑肽酶且未额外使用抑肽酶。有20例主动脉夹层患者和17例动脉粥样硬化性动脉瘤患者。22例患者采用左胸切口,17例采用胸骨正中切口。手术包括9例升主动脉置换、11例全弓置换、11例远端弓置换、3例降主动脉置换和5例胸腹主动脉置换。对照组为21例在深低温停循环和逆行脑灌注下手术但未使用抑肽酶的患者。在手术的不同阶段,即肝素给药前、肝素给药后、体外循环开始后60分钟和120分钟、鱼精蛋白给药后1小时以及鱼精蛋白给药后6小时,进行了凝血和纤溶检测,包括活化凝血时间、凝血酶原时间、活化部分凝血活酶时间、纤维蛋白原、抗凝血酶III、纤溶酶原、α2 -纤溶酶抑制剂、凝血酶 - 抗凝血酶复合物、纤溶酶抑制剂复合物、纤维蛋白降解产物和D -二聚体复合物。采用学生t检验、卡方检验和方差分析进行统计分析。抑肽酶组灌注后出血量较少,重症监护病房前24小时出血量也较少。血液检查显示,抑肽酶组体外循环停止后凝血酶原时间较高。抑肽酶组在体外循环期间及体外循环后凝血酶 - 抗凝血酶III复合物和α2 -纤溶酶抑制剂较高。活化凝血时间、活化部分凝血活酶时间、纤维蛋白原、抗凝血酶III、纤溶酶原、纤溶酶抑制剂复合物、纤维蛋白降解产物和D -二聚体复合物无差异。
在深低温停循环和逆行脑灌注下接受主动脉手术的患者中,低剂量抑肽酶的止血临床优势及无明显有害作用得到证实。然而,凝血和纤溶研究显示存在亚临床高凝状态。因此,在深低温停循环期间需要适当剂量的肝素。